Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
This study will contribute to the evaluation of long-term safety, tolerability and efficacy
of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.